StockData
Jasper Therapeutics, Inc. logo

Jasper Therapeutics, Inc. (JSPR) stock

JSPRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 5/30
$13.37−1.39 (-9.42%)

Close on Nov 12, 2026Market cap $444.88MP/E –Yield –

Jasper Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Jasper Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $36.70M, down 48.7% year over year. For fiscal 2025 it was $63.10M, up 13.0% from the year before. The highest annual figure on record is $63.10M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$63.10M+13.0%
FY2024Dec 31, 2024$55.82M+7.8%
FY2023Dec 31, 2023$51.79M+49.6%
FY2022Dec 31, 2022$34.63M+36.2%
FY2021Dec 31, 2021$25.42M+60.1%
FY2020Dec 31, 2020$15.88M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$5.14M-75.8%
Q1 FY2026Mar 31, 2026$5.81M-64.0%
Q4 FY2025Dec 31, 2025$11.36M-42.5%
Q3 FY2025Sep 30, 2025$14.39M-0.4%
Q2 FY2025Jun 30, 2025$21.20M+87.6%
Q1 FY2025Mar 31, 2025$16.16M+56.9%
Q4 FY2024Dec 31, 2024$19.77M+48.7%
Q3 FY2024Sep 30, 2024$14.46M+47.4%
Q2 FY2024Jun 30, 2024$11.30M+1241.6%
Q1 FY2024Mar 31, 2024$10.30M+14.1%
Q2 FY2023Jun 30, 2023$13.30M+63.5%
Q1 FY2023Mar 31, 2023$9.81M+19.7%
Q4 FY2022Dec 31, 2022$842.00K-90.3%
Q3 FY2022Sep 30, 2022$9.02M+25.5%
Q2 FY2022Jun 30, 2022$8.14M+57.8%
Q1 FY2022Mar 31, 2022$8.19M+85.2%
Q4 FY2021Dec 31, 2021$8.66M+86.3%
Q3 FY2021Sep 30, 2021$7.19M+59.0%
Q2 FY2021Jun 30, 2021$5.16M–
Q1 FY2021Mar 31, 2021$4.42M–
Q4 FY2020Dec 31, 2020$4.65M–
Q3 FY2020Sep 30, 2020$4.52M–

More Jasper Therapeutics figures

See a number that looks wrong?